Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

- PMLiVE

Clinical trials enter the genomic age

Looking at the factors driving this change and assessing the benefits

- PMLiVE

Dr Andrew Webber joins Life Healthcare Communications

He becomes a medical director at the agency

- PMLiVE

NHS marks its Twitter debut with story-sharing initiative

Three-month project will see a patient or staff member take over the new account

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

EpiDemic

Getting serious about drug pricing

Astellas bolsters oncology clinical development leadership

Dr Steven Benner joins while Dr Anne Keating is promoted

- PMLiVE

Immuno-oncology’s evolution: implications for pharma market researche

Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached...

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

Lucid Group: What medical communications means to us

Katherine Duxbury, Scientific Director at Lucid, explains what medical communications means to Lucid: What we do, how we do it and what makes us different.

Lucid Group Communications Limited

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links